September 15, 2017 : Successful Industrial GMP Manufacturing of RIBOXXIM, a Novel and Highly Potent Toll-like 3 Ligand for Immunotherapy of Cancer

RIBOXX PHARMACEUTICALS, a biotech company developing Toll-like-receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and ACCINOV, a pharmaceutical establishment for experimental drug products, today announced the successful industrial GMP manufacturing, including packaging and quality control of RIBOXXIM®, a novel and highly potent Toll-like Receptor 3 (TLR3)-ligand.

Press release